111 results on '"Pries‐Heje, Mia"'
Search Results
2. Recurrence of bacteremia and infective endocarditis according to bacterial species of index endocarditis episode
- Author
-
Østergaard, Lauge, Voldstedlund, Marianne, Bruun, Niels Eske, Bundgaard, Henning, Iversen, Kasper, Pries-Heje, Mia Marie, Hadji-Turdeghal, Katra, Graversen, Peter L., Moser, Claus, Andersen, Christian Østergaard, Søgaard, Kirstine Kobberøe, Køber, Lars, and Fosbøl, Emil Loldrup
- Published
- 2023
- Full Text
- View/download PDF
3. Association Between Vegetation Size and Outcome in the Partial Oral Antibiotic Endocarditis Treatment Trial
- Author
-
Carter-Storch, Rasmus, Pries-Heje, Mia Marie, Povlsen, Jonas A., Christensen, Ulrik, Gill, Sabine U., Hjulmand, Julie Glud, Bruun, Niels E., Elming, Hanne, Madsen, Trine, Fuursted, Kurt, Schultz, Martin, Christensen, Jens J., Rosenvinge, Flemming, Helweg-Larsen, Jannik, Fosbøl, Emil, Køber, Lars, Torp-Pedersen, Christian, Tønder, Niels, Moser, Claus, Iversen, Kasper, Bundgaard, Henning, and Ihlemann, Nikolaj
- Published
- 2024
- Full Text
- View/download PDF
4. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
- Author
-
Pérez-Alós, Laura, Hansen, Cecilie Bo, Almagro Armenteros, Jose Juan, Madsen, Johannes Roth, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Pries-Heje, Mia Marie, Bayarri-Olmos, Rafael, Jarlhelt, Ida, Hamm, Sebastian Rask, Møller, Dina Leth, Sørensen, Erik, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Bundgaard, Henning, Nielsen, Susanne Dam, Iversen, Kasper Karmark, and Garred, Peter
- Published
- 2023
- Full Text
- View/download PDF
5. Abstract 17647: Potential Candidates for Partial Oral Treatment in Patients With Endocarditis at a US Center
- Author
-
Pries-Heje, Mia, Connolly, Erin, Hartman, Dylan, Kim, Andy, Joyce, Mary-Ruth, Itoh, Akinobu, Cunningham, Mark, Ogara, Patrick T, Sun, Yee-Ping, Slavin, Samuel, Maguire, James, Aghayev, Ayaz, Weber, Brittany N, Di Carli, Marcelo, Suzuki, Joji, Iversen, Kasper, Baden, Lindsey, Bundgaard, Henning, and Woolley, Ann
- Published
- 2023
- Full Text
- View/download PDF
6. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
- Author
-
Heftdal, Line Dam, Pérez-Alós, Laura, Hasselbalch, Rasmus Bo, Hansen, Cecilie Bo, Hamm, Sebastian Rask, Møller, Dina Leth, Pries-Heje, Mia, Fogh, Kamille, Gerstoft, Jan, Grønbæk, Kirsten, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Sørensen, Erik, Hilsted, Linda, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Sabin, Caroline, and Nielsen, Susanne Dam
- Published
- 2023
- Full Text
- View/download PDF
7. Self-assessed health status and associated mortality in endocarditis: secondary findings from the POET trial
- Author
-
Bundgaard, Johan S., Iversen, Kasper, Pries-Heje, Mia, Ihlemann, Nikolaj, Gill, Sabine U., Madsen, Trine, Elming, Hanne, Povlsen, Jonas A., Bruun, Niels E., Høfsten, Dan E., Fuursted, Kurt, Christensen, Jens J., Schultz, Martin, Rosenvinge, Flemming, Helweg‑Larsen, Jannik, Køber, Lars, Torp‑Pedersen, Christian, Fosbøl, Emil L., Tønder, Niels, Moser, Claus, Bundgaard, Henning, and Mogensen, Ulrik M.
- Published
- 2022
- Full Text
- View/download PDF
8. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines
- Author
-
Hamm, Sebastian Rask, primary, Loft, Josefine Amalie, additional, Pérez-Alós, Laura, additional, Heftdal, Line Dam, additional, Hansen, Cecilie Bo, additional, Møller, Dina Leth, additional, Pries-Heje, Mia Marie, additional, Hasselbalch, Rasmus Bo, additional, Fogh, Kamille, additional, Hald, Annemette, additional, Ostrowski, Sisse Rye, additional, Frikke-Schmidt, Ruth, additional, Sørensen, Erik, additional, Hilsted, Linda, additional, Bundgaard, Henning, additional, Garred, Peter, additional, Iversen, Kasper, additional, Perch, Michael, additional, Sørensen, Søren Schwartz, additional, Rasmussen, Allan, additional, Sabin, Caroline A., additional, and Nielsen, Susanne Dam, additional
- Published
- 2024
- Full Text
- View/download PDF
9. Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers
- Author
-
Iversen, Kasper, Kristensen, Jonas Henrik, Hasselbalch, Rasmus Bo, Pries-Heje, Mia, Nielsen, Pernille Brok, Knudsen, Andreas Dehlbæk, Fogh, Kamille, Norsk, Jakob Boesgaard, Andersen, Ove, Fischer, Thea Køhler, Juul Jensen, Claus Antonio, Torp-Pedersen, Christian, Rungby, Jørgen, Ditlev, Sisse Bolm, Hageman, Ida, Møgelvang, Rasmus, Gybel-Brask, Mikkel, Dessau, Ram B., Sørensen, Erik, Harritshøj, Lene, Folke, Fredrik, Sten, Curt, Engel Møller, Maria Elizabeth, Benfield, Thomas, Ullum, Henrik, Jørgensen, Charlotte Sværke, Erikstrup, Christian, Ostrowski, Sisse R., Nielsen, Susanne Dam, and Bundgaard, Henning
- Published
- 2022
- Full Text
- View/download PDF
10. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
- Author
-
Pérez-Alós, Laura, Armenteros, Jose Juan Almagro, Madsen, Johannes Roth, Hansen, Cecilie Bo, Jarlhelt, Ida, Hamm, Sebastian Rask, Heftdal, Line Dam, Pries-Heje, Mia Marie, Møller, Dina Leth, Fogh, Kamille, Hasselbalch, Rasmus Bo, Rosbjerg, Anne, Brunak, Søren, Sørensen, Erik, Larsen, Margit Anita Hørup, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Bayarri-Olmos, Rafael, Hilsted, Linda Maria, Iversen, Kasper Karmark, Bundgaard, Henning, Nielsen, Susanne Dam, and Garred, Peter
- Published
- 2022
- Full Text
- View/download PDF
11. The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial
- Author
-
Bundgaard, Johan S., Iversen, Kasper, Pries-Heje, Mia, Ihlemann, Nikolaj, Bak, Theis S., Østergaard, Lauge, Gill, Sabine U., Madsen, Trine, Elming, Hanne, Jensen, Kaare T., Bruun, Niels E., Høfsten, Dan E., Fuursted, Kurt, Christensen, Jens J., Schultz, Martin, Rosenvinge, Flemming, Schønheyder, Henrik C., Helweg-Larsen, Jannik, Køber, Lars, Torp-Pedersen, Christian, Fosbøl, Emil L., Tønder, Niels, Moser, Claus, Bundgaard, Henning, and Mogensen, Ulrik M.
- Published
- 2022
- Full Text
- View/download PDF
12. Implications of Age for the Diagnostic and Prognostic Value of Cardiac Troponin T and I.
- Author
-
Hasselbalch, Rasmus Bo, Schytz, Philip Andreas, Schultz, Martin, Sindet-Pedersen, Caroline, Kristensen, Jonas Henrik, Strandkjær, Nina, Knudsen, Sophie Sander, Pries-Heje, Mia, Pareek, Manan, Kragholm, Kristian H, Carlson, Nicholas, Schou, Morten, Andersen, Mikkel Porsborg, Bundgaard, Henning, Torp-Pedersen, Christian, and Iversen, Kasper Karmark
- Published
- 2024
- Full Text
- View/download PDF
13. Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
- Author
-
Heftdal, Line Dam, Hansen, Cecilie Bo, Hamm, Sebastian Rask, Pérez-Alós, Laura, Fogh, Kamille, Pries-Heje, Mia, Hasselbalch, Rasmus Bo, Møller, Dina Leth, Gang, Anne Ortved, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Sørensen, Erik, Hilsted, Linda, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Sabin, Caroline, Nielsen, Susanne Dam, Grønbæk, Kirsten, Heftdal, Line Dam, Hansen, Cecilie Bo, Hamm, Sebastian Rask, Pérez-Alós, Laura, Fogh, Kamille, Pries-Heje, Mia, Hasselbalch, Rasmus Bo, Møller, Dina Leth, Gang, Anne Ortved, Ostrowski, Sisse Rye, Frikke-Schmidt, Ruth, Sørensen, Erik, Hilsted, Linda, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Sabin, Caroline, Nielsen, Susanne Dam, and Grønbæk, Kirsten
- Abstract
To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233 patients with lymphoid malignancies (chronic lymphocytic B-cell leukemia: 73 (31.3%), lymphoma: 89 (38.2%), multiple myeloma/amyloidosis: 71 (30.5%)), who received an Omicron-adapted mRNA-based COVID-19 vaccine. IgG and neutralizing antibodies specific for the receptor-binding domain (RBD) of SARS-CoV-2 were measured using ELISA-based methods. Differences in antibody concentrations and neutralizing capacity and associations with risk factors were assessed using mixed-effects models. Over the period of vaccination with an Omicron-adapted COVID-19 vaccine, the predicted mean concentration of anti-RBD IgG increased by 0.09 log10 AU/mL/month (95% CI: 0.07; 0.11) in patients with lymphoid malignancies across diagnoses. The predicted mean neutralizing capacity increased by 0.9 percent points/month (95% CI: 0.2; 1.6). We found no associations between the increase in antibody concentration or neutralizing capacity and the variant included in the adapted vaccine. In conclusion, a discrete increase in antibody concentrations and neutralizing capacity was found over the course of Omicron-adapted vaccination in patients with lymphoid malignancies regardless of the adapted vaccine variant, indicating a beneficial effect of Omicron-adapted booster vaccination in this population.
- Published
- 2024
14. Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
- Author
-
Heftdal, Line Dam, primary, Hansen, Cecilie Bo, additional, Hamm, Sebastian Rask, additional, Pérez-Alós, Laura, additional, Fogh, Kamille, additional, Pries-Heje, Mia, additional, Hasselbalch, Rasmus Bo, additional, Møller, Dina Leth, additional, Gang, Anne Ortved, additional, Ostrowski, Sisse Rye, additional, Frikke-Schmidt, Ruth, additional, Sørensen, Erik, additional, Hilsted, Linda, additional, Bundgaard, Henning, additional, Garred, Peter, additional, Iversen, Kasper, additional, Sabin, Caroline, additional, Nielsen, Susanne Dam, additional, and Grønbæk, Kirsten, additional
- Published
- 2023
- Full Text
- View/download PDF
15. 2409. Potential candidates for partial oral treatment in patients with endocarditis at a US center
- Author
-
Pries-Heje, Mia M, primary, Kim, Andy J, additional, Joyce, Mary-Ruth M, additional, Hartman, Dylan J, additional, Connolly, Erin M, additional, Itoh, Akinobu, additional, Cunningham, Mark, additional, O’Gara, Patrick, additional, Sun, Yee-Ping, additional, Maguire, James, additional, Aghayev, Ayaz, additional, Weber, Brittany N, additional, Di Carli, Marcelo, additional, Suzuki, Joji, additional, Ramirez, Yesenia Buenrostro, additional, Iversen, Kasper K, additional, Baden, Lindsey R, additional, Bundgaard, Henning, additional, and Woolley, Ann E, additional
- Published
- 2023
- Full Text
- View/download PDF
16. Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis
- Author
-
Bock, Magnus, primary, Van Hasselt, Johan G C, additional, Schwartz, Franziska, additional, Wang, Hengzhuang, additional, Høiby, Niels, additional, Fuursted, Kurt, additional, Ihlemann, Nikolaj, additional, Gill, Sabine, additional, Christiansen, Ulrik, additional, Bruun, Niels Eske, additional, Elming, Hanne, additional, Povlsen, Jonas A, additional, Køber, Lars, additional, Høfsten, Dan E, additional, Fosbøl, Emil L, additional, Pries-Heje, Mia M, additional, Christensen, Jens Jørgen, additional, Rosenvinge, Flemming S, additional, Torp-Pedersen, Christian, additional, Helweg-Larsen, Jannik, additional, Tønder, Niels, additional, Iversen, Kasper, additional, Bundgaard, Henning, additional, and Moser, Claus, additional
- Published
- 2023
- Full Text
- View/download PDF
17. Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
- Author
-
Holm-Yildiz, Sonja, primary, Dysgaard, Tina, additional, Krag, Thomas, additional, Pedersen, Britt Stævnsbo, additional, Hamm, Sebastian Rask, additional, Pérez-Alós, Laura, additional, Hansen, Cecilie Bo, additional, Pries-Heje, Mia Marie, additional, Heftdal, Line Dam, additional, Hasselbalch, Rasmus Bo, additional, Fogh, Kamille, additional, Madsen, Johannes Roth, additional, Frikke-Schmidt, Ruth, additional, Hilsted, Linda Maria, additional, Sørensen, Erik, additional, Ostrowski, Sisse Rye, additional, Bundgaard, Henning, additional, Garred, Peter, additional, Iversen, Kasper, additional, Nielsen, Susanne Dam, additional, and Vissing, John, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies
- Author
-
Heftdal, Line Dam, primary, Hamm, Sebastian Rask, additional, Pérez‐Alós, Laura, additional, Madsen, Johannes Roth, additional, Armenteros, Jose Juan Almagro, additional, Fogh, Kamille, additional, Kronborg, Christoffer Cronwald, additional, Vallentin, Anders Pommer, additional, Hasselbalch, Rasmus Bo, additional, Møller, Dina Leth, additional, Hansen, Cecilie Bo, additional, Pries‐Heje, Mia, additional, Gang, Anne Ortved, additional, Ostrowski, Sisse Rye, additional, Frikke‐Schmidt, Ruth, additional, Sørensen, Erik, additional, Hilsted, Linda, additional, Bundgaard, Henning, additional, Iversen, Kasper, additional, Garred, Peter, additional, Nielsen, Susanne Dam, additional, and Grønbæk, Kirsten, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Clinical implementation of partial oral treatment in infective endocarditis: the Danish POETry study.
- Author
-
Pries-Heje, Mia Marie, Hjulmand, Julie Glud, Lenz, Ingrid Try, Hasselbalch, Rasmus Bo, Povlsen, Jonas Agerlund, Ihlemann, Nikolaj, Køber, Nana, Tofterup, Marlene Lyngborg, Østergaard, Lauge, Dalsgaard, Morten, Faurholt-Jepsen, Daniel, Wienberg, Malene, Christiansen, Ulrik, Bruun, Niels Eske, Fosbøl, Emil, Moser, Claus, Iversen, Kasper Karmark, and Bundgaard, Henning
- Subjects
INFECTIVE endocarditis ,ORAL drug administration ,POETRY studies ,ENTEROCOCCUS faecalis ,CARDIAC surgery - Abstract
Background and Aims In the Partial Oral Treatment of Endocarditis (POET) trial, stabilized patients with left-sided infective endocarditis (IE) were randomized to oral step-down antibiotic therapy (PO) or conventional continued intravenous antibiotic treatment (IV), showing non-inferiority after 6 months. In this study, the first guideline-driven clinical implementation of the oral step-down POET regimen was examined. Methods Patients with IE, caused by Staphylococcus aureus , Enterococcus faecalis , Streptococcus spp. or coagulase-negative staphylococci diagnosed between May 2019 and December 2020 were possible candidates for initiation of oral step-down antibiotic therapy, at the discretion of the treating physician. The composite primary outcome in patients finalizing antibiotic treatment consisted of embolic events, unplanned cardiac surgery, relapse of bacteraemia and all-cause mortality within 6 months. Results A total of 562 patients [median age 74 years (IQR, interquartile range, 65–80), 70% males] with IE were possible candidates; PO was given to 240 (43%) patients and IV to 322 (57%) patients. More patients in the IV group had IE caused by S. aureus , or had an intra-cardiac abscess, or a pacemaker and more were surgically treated. The primary outcome occurred in 30 (13%) patients in the PO group and in 59 (18%) patients in the IV group (P =.051); in the PO group, 20 (8%) patients died vs. 46 (14%) patients in the IV group (P =.024). PO-treated patients had a shorter median length of stay [PO 24 days (IQR 17–36) vs. IV 43 days (IQR 32–51), P <.001]. Conclusions After clinical implementation of the POET regimen almost half of the possible candidates with IE received oral step-down antibiotic therapy. Patients in the IV group had more serious risk factors for negative outcomes. At 6-month follow-up, there was a numerically but not statistically significant difference towards a lower incidence of the primary outcome, a lower incidence of all-cause mortality and a reduced length of stay in the PO group. Due to the observational design of the study, the lower mortality may to some extent reflect selection bias and unmeasured confounding. Clinical implementation of PO regimens seemed feasible and safe. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
- Author
-
Madsen, Johannes Roth, primary, Holm, Bettina Eide, additional, Pérez-Alós, Laura, additional, Bayarri-Olmos, Rafael, additional, Rosbjerg, Anne, additional, Fogh, Kamille, additional, Pries-Heje, Mia Marie, additional, Møller, Dina Leth, additional, Hansen, Cecilie Bo, additional, Heftdal, Line Dam, additional, Hasselbalch, Rasmus Bo, additional, Hamm, Sebastian Rask, additional, Frikke-Schmidt, Ruth, additional, Hilsted, Linda, additional, Nielsen, Susanne Dam, additional, Iversen, Kasper Karmark, additional, Bundgaard, Henning, additional, and Garred, Peter, additional
- Published
- 2023
- Full Text
- View/download PDF
21. Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy
- Author
-
Bock, Magnus, primary, Theut, Anna Marie, additional, van Hasselt, Johan G C, additional, Wang, Hengzhuang, additional, Fuursted, Kurt, additional, Høiby, Niels, additional, Lerche, Christian Johann, additional, Ihlemann, Nikolaj, additional, Gill, Sabine, additional, Christiansen, Ulrik, additional, Nielsen, Hans Linde, additional, Lemming, Lars, additional, Elming, Hanne, additional, Povlsen, Jonas A, additional, Bruun, Niels Eske, additional, Høfsten, Dan, additional, Fosbøl, Emil L, additional, Køber, Lars, additional, Schultz, Martin, additional, Pries-Heje, Mia M, additional, Kristensen, Jonas Henrik, additional, Christensen, Jens Jørgen, additional, Rosenvinge, Flemming S, additional, Pedersen, Christian Torp, additional, Helweg-Larsen, Jannik, additional, Tønder, Niels, additional, Iversen, Kasper, additional, Bundgaard, Henning, additional, and Moser, Claus, additional
- Published
- 2023
- Full Text
- View/download PDF
22. Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
- Author
-
Holm-Yildiz, Sonja, Dysgaard, Tina, Krag, Thomas, Pedersen, Britt Stævnsbo, Hamm, Sebastian Rask, Pérez-Alós, Laura, Hansen, Cecilie Bo, Pries-Heje, Mia Marie, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Fogh, Kamille, Madsen, Johannes Roth, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Sørensen, Erik, Ostrowski, Sisse Rye, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Nielsen, Susanne Dam, Vissing, John, Holm-Yildiz, Sonja, Dysgaard, Tina, Krag, Thomas, Pedersen, Britt Stævnsbo, Hamm, Sebastian Rask, Pérez-Alós, Laura, Hansen, Cecilie Bo, Pries-Heje, Mia Marie, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Fogh, Kamille, Madsen, Johannes Roth, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Sørensen, Erik, Ostrowski, Sisse Rye, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Nielsen, Susanne Dam, and Vissing, John
- Abstract
We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379)., We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).
- Published
- 2023
23. Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
- Author
-
Madsen, Johannes Roth, Holm, Bettina Eide, Pérez-Alós, Laura, Bayarri-Olmos, Rafael, Rosbjerg, Anne, Fogh, Kamille, Pries-Heje, Mia Marie, Møller, Dina Leth, Hansen, Cecilie Bo, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Hamm, Sebastian Rask, Frikke-Schmidt, Ruth, Hilsted, Linda, Nielsen, Susanne Dam, Iversen, Kasper Karmark, Bundgaard, Henning, Garred, Peter, Madsen, Johannes Roth, Holm, Bettina Eide, Pérez-Alós, Laura, Bayarri-Olmos, Rafael, Rosbjerg, Anne, Fogh, Kamille, Pries-Heje, Mia Marie, Møller, Dina Leth, Hansen, Cecilie Bo, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Hamm, Sebastian Rask, Frikke-Schmidt, Ruth, Hilsted, Linda, Nielsen, Susanne Dam, Iversen, Kasper Karmark, Bundgaard, Henning, and Garred, Peter
- Abstract
Knowledge about the effect of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on immunity reflected in the saliva is sparse. We examined the antibody response in saliva compared to that in serum 2 and 6 months after the first vaccination with the BNT162b2 vaccine. Four hundred fifty-nine health care professionals were included in a prospective observational study measuring antibody levels in saliva and corresponding serum samples at 2 and 6 months after BNT162b2 vaccination. Vaccinated, previously SARS-CoV-2-infected individuals (hybrid immunity) had higher IgG levels in saliva at 2 months than vaccinated, infection-naive individuals (P , 0.001). After 6 months, saliva IgG levels declined in both groups (P , 0.001), with no difference between groups (P = 0.37). Furthermore, serum IgG levels declined from 2 to 6 months in both groups (P , 0.001). IgG antibodies in saliva and serum correlated in individuals with hybrid immunity at 2 and 6 months (r = 0.58, P = 0.001, and r = 0.53, P = 0.052, respectively). In vaccinated, infection-naive individuals, a correlation was observed at 2 months (r = 0.42, P , 0.001) but not after 6 months (r = 0.14, P = 0.055). IgA and IgM antibodies were hardly detectable in saliva at any time point, regardless of previous infection. In serum, IgA was detected at 2 months in previously infected individuals. BNT162b2 vaccination induced a detectable IgG anti-SARS-CoV-2 RBD response in saliva at both 2 and 6 months after vaccination, being more prominent in previously infected than infection-naive individuals. However, a significant decrease in salivary IgG was observed after 6 months, suggesting a rapid decline in antibody-mediated saliva immunity against SARS-CoV-2, after both infection and systemic vaccination. IMPORTANCE Knowledge about the persistence of salivary immunity after SARS-CoV-2 vaccination is limited, and information on this topic could prove important for vaccine strategy and development. W
- Published
- 2023
24. Infective Endocarditis Antibiotic Prophylaxis:Review of the Evidence and Guidelines
- Author
-
Pries-Heje, Mia M., Bundgaard, Henning, Iversen, Kasper K., Baden, Lindsey R., Woolley, Ann E., Pries-Heje, Mia M., Bundgaard, Henning, Iversen, Kasper K., Baden, Lindsey R., and Woolley, Ann E.
- Abstract
Purpose of Review The question of antibiotic prophylaxis and its role in prevention of infective endocarditis (IE) remains controversial, with differing recommendations from international societies. The aim of this review was to compare and contrast current recommendations on antibiotic prophylaxis for IE by the American Heart Association (AHA), the European Society of Cardiology (ESC), and the National Institute for Health and Care Excellence (NICE) and highlight the evidence supporting these recommendations. Recent Findings International guidelines for administration of antibiotic prophylaxis for prevention of IE are largely unchanged since 2009. Studies on the impact of the more restrictive antibiotic prophylaxis recommendations are conflicting, with several studies suggesting lack of adherence to current guidance from the ESC (2015), NICE (2016), and AHA (2021). Summary The question of antibiotic prophylaxis in patients with IE remains controversial, with differing recommendations from international societies. Despite the change in guidelines more than 15 years ago, lack of adherence to current guidelines persists. Due to the lack of high-quality evidence and the conflicting results from observational studies along with the lack of randomized clinical trials, the question of whether to recommend antibiotic prophylaxis or not in certain patient populations remains unanswered and remains largely based on expert consensus opinion., Purpose of Review: The question of antibiotic prophylaxis and its role in prevention of infective endocarditis (IE) remains controversial, with differing recommendations from international societies. The aim of this review was to compare and contrast current recommendations on antibiotic prophylaxis for IE by the American Heart Association (AHA), the European Society of Cardiology (ESC), and the National Institute for Health and Care Excellence (NICE) and highlight the evidence supporting these recommendations. Recent Findings: International guidelines for administration of antibiotic prophylaxis for prevention of IE are largely unchanged since 2009. Studies on the impact of the more restrictive antibiotic prophylaxis recommendations are conflicting, with several studies suggesting lack of adherence to current guidance from the ESC (2015), NICE (2016), and AHA (2021). Summary: The question of antibiotic prophylaxis in patients with IE remains controversial, with differing recommendations from international societies. Despite the change in guidelines more than 15 years ago, lack of adherence to current guidelines persists. Due to the lack of high-quality evidence and the conflicting results from observational studies along with the lack of randomized clinical trials, the question of whether to recommend antibiotic prophylaxis or not in certain patient populations remains unanswered and remains largely based on expert consensus opinion.
- Published
- 2023
25. Clinical implementation of partial oral treatment in infective endocarditis:the Danish POETry study
- Author
-
Pries-Heje, Mia Marie, Hjulmand, Julie Glud, Lenz, Ingrid Try, Hasselbalch, Rasmus Bo, Povlsen, Jonas Agerlund, Ihlemann, Nikolaj, Køber, Nana, Tofterup, Marlene Lyngborg, Østergaard, Lauge, Dalsgaard, Morten, Faurholt-Jepsen, Daniel, Wienberg, Malene, Christiansen, Ulrik, Bruun, Niels Eske, Fosbøl, Emil, Moser, Claus, Iversen, Kasper Karmark, Bundgaard, Henning, Pries-Heje, Mia Marie, Hjulmand, Julie Glud, Lenz, Ingrid Try, Hasselbalch, Rasmus Bo, Povlsen, Jonas Agerlund, Ihlemann, Nikolaj, Køber, Nana, Tofterup, Marlene Lyngborg, Østergaard, Lauge, Dalsgaard, Morten, Faurholt-Jepsen, Daniel, Wienberg, Malene, Christiansen, Ulrik, Bruun, Niels Eske, Fosbøl, Emil, Moser, Claus, Iversen, Kasper Karmark, and Bundgaard, Henning
- Abstract
Background and In the Partial Oral Treatment of Endocarditis (POET) trial, stabilized patients with left-sided infective endocarditis (IE) were Aims randomized to oral step-down antibiotic therapy (PO) or conventional continued intravenous antibiotic treatment (IV), showing non-inferiority after 6 months. In this study, the first guideline-driven clinical implementation of the oral step-down POET regimen was examined. Methods Patients with IE, caused by Staphylococcus aureus, Enterococcus faecalis, Streptococcus spp. or coagulase-negative staphylococci diagnosed between May 2019 and December 2020 were possible candidates for initiation of oral step-down antibiotic therapy, at the discretion of the treating physician. The composite primary outcome in patients finalizing antibiotic treatment consisted of embolic events, unplanned cardiac surgery, relapse of bacteraemia and all-cause mortality within 6 months. Results A total of 562 patients [median age 74 years (IQR, interquartile range, 65–80), 70% males] with IE were possible candidates; PO was given to 240 (43%) patients and IV to 322 (57%) patients. More patients in the IV group had IE caused by S. aureus, or had an intra-cardiac abscess, or a pacemaker and more were surgically treated. The primary outcome occurred in 30 (13%) patients in the PO group and in 59 (18%) patients in the IV group (P = .051); in the PO group, 20 (8%) patients died vs. 46 (14%) patients in the IV group (P = .024). PO-treated patients had a shorter median length of stay [PO 24 days (IQR 17–36) vs. IV 43 days (IQR 32–51), P < .001]. Conclusions After clinical implementation of the POET regimen almost half of the possible candidates with IE received oral step-down antibiotic therapy. Patients in the IV group had more serious risk factors for negative outcomes. At 6-month follow-up, there was a numerically but not statistically significant difference towards a lower incidence of the primary outcome, a lower incidence of all-cause morta
- Published
- 2023
26. Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis
- Author
-
Bock, Magnus, Van Hasselt, Johan G C, Schwartz, Franziska, Wang, Hengzhuang, Høiby, Niels, Fuursted, Kurt, Ihlemann, Nikolaj, Gill, Sabine, Christiansen, Ulrik, Bruun, Niels Eske, Elming, Hanne, Povlsen, Jonas A, Køber, Lars, Høfsten, Dan E, Fosbøl, Emil L, Pries-Heje, Mia M, Christensen, Jens Jørgen, Rosenvinge, Flemming S, Torp-Pedersen, Christian, Helweg-Larsen, Jannik, Tønder, Niels, Iversen, Kasper, Bundgaard, Henning, Moser, Claus, Bock, Magnus, Van Hasselt, Johan G C, Schwartz, Franziska, Wang, Hengzhuang, Høiby, Niels, Fuursted, Kurt, Ihlemann, Nikolaj, Gill, Sabine, Christiansen, Ulrik, Bruun, Niels Eske, Elming, Hanne, Povlsen, Jonas A, Køber, Lars, Høfsten, Dan E, Fosbøl, Emil L, Pries-Heje, Mia M, Christensen, Jens Jørgen, Rosenvinge, Flemming S, Torp-Pedersen, Christian, Helweg-Larsen, Jannik, Tønder, Niels, Iversen, Kasper, Bundgaard, Henning, and Moser, Claus
- Abstract
Background Linezolid in combination with rifampicin has been used in treatment of infective endocarditis especially for patients infected with staphylococci. Objectives Because rifampicin has been reported to reduce the plasma concentration of linezolid, the present study aimed to characterize the population pharmacokinetics of linezolid for the purpose of quantifying an effect of rifampicin cotreatment. In addition, the possibility of compensation by dosage adjustments was evaluated. Patients and methods Pharmacokinetic measurements were performed in 62 patients treated with linezolid for left-sided infective endocarditis in the Partial Oral Endocarditis Treatment (POET) trial. Fifteen patients were cotreated with rifampicin. A total of 437 linezolid plasma concentrations were obtained. The pharmacokinetic data were adequately described by a one-compartment model with first-order absorption and first-order elimination. Results We demonstrated a substantial increase of linezolid clearance by 150% (95% CI: 78%–251%), when combined with rifampicin. The final model was evaluated by goodness-of-fit plots showing an acceptable fit, and a visual predictive check validated the model. Model-based dosing simulations showed that rifampicin cotreatment decreased the PTA of linezolid from 94.3% to 34.9% and from 52.7% to 3.5% for MICs of 2 mg/L and 4 mg/L, respectively. Conclusions A substantial interaction between linezolid and rifampicin was detected in patients with infective endocarditis, and the interaction was stronger than previously reported. Model-based simulations showed that increasing the linezolid dose might compensate without increasing the risk of adverse effects to the same degree., BACKGROUND: Linezolid in combination with rifampicin has been used in treatment of infective endocarditis especially for patients infected with staphylococci.OBJECTIVES: Because rifampicin has been reported to reduce the plasma concentration of linezolid, the present study aimed to characterize the population pharmacokinetics of linezolid for the purpose of quantifying an effect of rifampicin cotreatment. In addition, the possibility of compensation by dosage adjustments was evaluated.PATIENTS AND METHODS: Pharmacokinetic measurements were performed in 62 patients treated with linezolid for left-sided infective endocarditis in the Partial Oral Endocarditis Treatment (POET) trial. Fifteen patients were cotreated with rifampicin. A total of 437 linezolid plasma concentrations were obtained. The pharmacokinetic data were adequately described by a one-compartment model with first-order absorption and first-order elimination.RESULTS: We demonstrated a substantial increase of linezolid clearance by 150% (95% CI: 78%-251%), when combined with rifampicin. The final model was evaluated by goodness-of-fit plots showing an acceptable fit, and a visual predictive check validated the model. Model-based dosing simulations showed that rifampicin cotreatment decreased the PTA of linezolid from 94.3% to 34.9% and from 52.7% to 3.5% for MICs of 2 mg/L and 4 mg/L, respectively.CONCLUSIONS: A substantial interaction between linezolid and rifampicin was detected in patients with infective endocarditis, and the interaction was stronger than previously reported. Model-based simulations showed that increasing the linezolid dose might compensate without increasing the risk of adverse effects to the same degree.
- Published
- 2023
27. Attainment of Target Antibiotic Levels by Oral Treatment of Left-sided Infective Endocarditis:A POET Substudy
- Author
-
Bock, Magnus, Theut, Anna Marie, van Hasselt, Johan G. C., Wang, Hengzhuang, Fuursted, Kurt, Hoiby, Niels, Lerche, Christian Johann, Ihlemann, Nikolaj, Gill, Sabine, Christiansen, Ulrik, Nielsen, Hans Linde, Lemming, Lars, Elming, Hanne, Povlsen, Jonas A., Bruun, Niels Eske, Hofsten, Dan, Fosbøl, Emil L., Kober, Lars, Schultz, Martin, Pries-Heje, Mia M., Kristensen, Jonas Henrik, Christensen, Jens Jørgen, Rosenvinge, Flemming S., Pedersen, Christian Torp, Helweg-Larsen, Jannik, Tønder, Niels, Iversen, Kasper, Bundgaard, Henning, Moser, Claus, Bock, Magnus, Theut, Anna Marie, van Hasselt, Johan G. C., Wang, Hengzhuang, Fuursted, Kurt, Hoiby, Niels, Lerche, Christian Johann, Ihlemann, Nikolaj, Gill, Sabine, Christiansen, Ulrik, Nielsen, Hans Linde, Lemming, Lars, Elming, Hanne, Povlsen, Jonas A., Bruun, Niels Eske, Hofsten, Dan, Fosbøl, Emil L., Kober, Lars, Schultz, Martin, Pries-Heje, Mia M., Kristensen, Jonas Henrik, Christensen, Jens Jørgen, Rosenvinge, Flemming S., Pedersen, Christian Torp, Helweg-Larsen, Jannik, Tønder, Niels, Iversen, Kasper, Bundgaard, Henning, and Moser, Claus
- Abstract
Background In the POET (Partial Oral Endocarditis Treatment) trial, oral step-down therapy was noninferior to full-length intravenous antibiotic administration. The aim of the present study was to perform pharmacokinetic/pharmacodynamic analyses for oral treatments of infective endocarditis to assess the probabilities of target attainment (PTAs). Methods Plasma concentrations of oral antibiotics were measured at day 1 and 5. Minimal inhibitory concentrations (MICs) were determined for the bacteria causing infective endocarditis (streptococci, staphylococci, or enterococci). Pharmacokinetic/pharmacodynamic targets were predefined according to literature using time above MIC or the ratio of area under the curve to MIC. Population pharmacokinetic modeling and pharmacokinetic/pharmacodynamic analyses were done for amoxicillin, dicloxacillin, linezolid, moxifloxacin, and rifampicin, and PTAs were calculated. Results A total of 236 patients participated in this POET substudy. For amoxicillin and linezolid, the PTAs were 88%–100%. For moxifloxacin and rifampicin, the PTAs were 71%–100%. Using a clinical breakpoint for staphylococci, the PTAs for dicloxacillin were 9%–17%. Seventy-four patients at day 1 and 65 patients at day 5 had available pharmacokinetic and MIC data for 2 oral antibiotics. Of those, 13 patients at day 1 and 14 patients at day 5 did only reach the target for 1 antibiotic. One patient did not reach target for any of the 2 antibiotics. Conclusions For the individual orally administered antibiotic, the majority reached the target level. Patients with sub-target levels were compensated by the administration of 2 different antibiotics. The findings support the efficacy of oral step-down antibiotic treatment in patients with infective endocarditis., Background. In the POET (Partial Oral Endocarditis Treatment) trial, oral step-down therapy was noninferior to full-length intravenous antibiotic administration. The aim of the present study was to perform pharmacokinetic/pharmacodynamic analyses for oral treatments of infective endocarditis to assess the probabilities of target attainment (PTAs).Methods. Plasma concentrations of oral antibiotics were measured at day 1 and 5. Minimal inhibitory concentrations (MICs) were determined for the bacteria causing infective endocarditis (streptococci, staphylococci, or enterococci). Pharmacokinetic/pharmacodynamic targets were predefined according to literature using time above MIC or the ratio of area under the curve to MIC. Population pharmacokinetic modeling and pharmacokinetic/pharmacodynamic analyses were done for amoxicillin, dicloxacillin, linezolid, moxifloxacin, and rifampicin, and PTAs were calculated.Results. A total of 236 patients participated in this POET substudy. For amoxicillin and linezolid, the PTAs were 88%-100%. For moxifloxacin and rifampicin, the PTAs were 71%-100%. Using a clinical breakpoint for staphylococci, the PTAs for dicloxacillin were 9%-17%. Seventy-four patients at day 1 and 65 patients at day 5 had available pharmacokinetic and MIC data for 2 oral antibiotics. Of those, 13 patients at day 1 and 14 patients at day 5 did only reach the target for 1 antibiotic. One patient did not reach target for any of the 2 antibiotics.Conclusions. For the individual orally administered antibiotic, the majority reached the target level. Patients with sub-target levels were compensated by the administration of 2 different antibiotics. The findings support the efficacy of oral step-down antibiotic treatment in patients with infective endocarditis.
- Published
- 2023
28. Predictive and prognostic value of different cardiac troponin assays:a nationwide register-based cohort study
- Author
-
Hasselbalch, Rasmus Bo, Schultz, Martin, Schytz, Philip Andreas, Kristensen, Jonas Henrik, Strandkjaer, Nina, Pries-Heje, Mia, Carlson, Nicholas, Schou, Morten, Bundgaard, Henning, Torp-Pedersen, Christian, Iversen, Kasper Karmark, Hasselbalch, Rasmus Bo, Schultz, Martin, Schytz, Philip Andreas, Kristensen, Jonas Henrik, Strandkjaer, Nina, Pries-Heje, Mia, Carlson, Nicholas, Schou, Morten, Bundgaard, Henning, Torp-Pedersen, Christian, and Iversen, Kasper Karmark
- Abstract
Guidelines do not differentiate between the available assays of cardiac troponin (cTn). We compared the prognostic and predictive ability of cTn assays, Aims Guidelines do not differentiate between the available assays of cardiac troponin (cTn). We compared the prognostic and predictive ability of cTn assays. Methods and results This was a nationwide cohort study of patients with acute coronary syndrome (ACS) and >= 2 cTn measurements of one of four assays: Roche high-sensitivity cTnT (hs-cTnT), Abbott high sensitivity cTnI (hs-cTnI), Siemens Vista cTnI, and Siemens cTnI Ultra. Data were collected from Danish registries from 2009-18. Peak cTn concentration normalized to the 99(th) percentile was used. Outcomes were myocardial infarction (MI) during admission, one-year all-cause-, cardiovascular-, and non-cardiovascular mortality. Receiver operating characteristics and logistic regression calculating odds ratios (OR) were used. A total of 90 705 patients were included, of which 20 550 (23%) had MI. Siemens Vista cTnI was the strongest predictor of MI, Area under the curve (auc) 0.93 (95% CI 0.93-0.93). In 1 year 9012 (9.9%) of patients had died. An inverted U-shape relationship was observed between concentration of cTn and all-cause mortality. Hs-cTnT OR 21.3 (95% CI 18.4-24.8) at 2-5 times the 99(th) percentile and 12.1 (95% CI 10.3-14.1) for concentrations >100 times the 99(th) percentile. The inverted U-shape relationship was only present for non-cardiovascular mortality. The strongest predictor of cardiovascular mortality was hs-cTnT, OR 11.3 (95% CI 6.4-21.8) at 1-2 times the 99(th) percentile and 88.8 (95% CI 53.2-163.0) for concentrations >100 times the 99(th) percentile. Conclusion Siemens Vista cTnI was the strongest predictor of MI and hs-cTnT was the strongest predictor of mortality. An inverted U-shape relationship was observed between cTn concentration and non-cardiovascular mortality.
- Published
- 2023
29. Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study
- Author
-
Kvist-Hansen, Amanda, primary, Pérez-Alós, Laura, additional, Al-Sofi, Rownaq Fares, additional, Heftdal, Line Dam, additional, Hamm, Sebastian Rask, additional, Møller, Dina Leth, additional, Pries-Heje, Mia Marie, additional, Fogh, Kamille, additional, Hansen, Cecilie Bo, additional, Hasselbalch, Rasmus Bo, additional, Madsen, Johannes Roth, additional, Armenteros, Jose Juan Almagro, additional, Frikke-Schmidt, Ruth, additional, Hilsted, Linda, additional, Sørensen, Erik, additional, Ostrowski, Sisse Rye, additional, Bundgaard, Henning, additional, Nielsen, Susanne Dam, additional, Iversen, Kasper, additional, Zachariae, Claus, additional, Garred, Peter, additional, and Skov, Lone, additional
- Published
- 2023
- Full Text
- View/download PDF
30. Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection
- Author
-
Rezahosseini, Omid, primary, Hamm, Sebastian Rask, additional, Heftdal, Line Dam, additional, Pérez-Alós, Laura, additional, Møller, Dina Leth, additional, Perch, Michael, additional, Madsen, Johannes Roth, additional, Hald, Annemette, additional, Hansen, Cecilie Bo, additional, Armenteros, Jose Juan Almagro, additional, Pries-Heje, Mia Marie, additional, Hasselbalch, Rasmus Bo, additional, Fogh, Kamille, additional, Frikke-Schmidt, Ruth, additional, Hilsted, Linda Maria, additional, Sørensen, Erik, additional, Ostrowski, Sisse Rye, additional, Harboe, Zitta Barrella, additional, Iversen, Kasper, additional, Bundgaard, Henning, additional, Sørensen, Søren Schwartz, additional, Rasmussen, Allan, additional, Garred, Peter, additional, and Nielsen, Susanne Dam, additional
- Published
- 2023
- Full Text
- View/download PDF
31. Results From the Clinical Implementation of Partial Oral Treatment of Patients With Infectious Endocarditis; A Nationwide Study. Time for Poetry?
- Author
-
Pries-Heje, Mia M, Lenz, Ingrid T, Hjulmand, Julie G, Haselbalch, Rasmus B, Povlsen, Jonas A, Ihlemann, Nilkolaj, Køber, Nana, Wienberg, Malene, Tofterup, Marlene L, Christiansen, Ulrik, Bruun, Niels E, Fosbøl, Emil, Moser, Claus, Iversen, Kasper, and Bundgaard, Henning
- Published
- 2022
32. Predictive and prognostic value of different cardiac troponin assays: a nationwide register-based cohort study
- Author
-
Hasselbalch, Rasmus B, primary, Schultz, Martin, additional, Schytz, Philip A, additional, Kristensen, Jonas H, additional, Strandkjær, Nina, additional, Pries-Heje, Mia, additional, Carlson, Nicholas, additional, Schou, Morten, additional, Bundgaard, Henning, additional, Torp-Pedersen, Christian, additional, and Iversen, Kasper K, additional
- Published
- 2022
- Full Text
- View/download PDF
33. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
- Author
-
Harboe, Zitta Barrella, primary, Hamm, Sebastian Rask, additional, Pérez-Alós, Laura, additional, Sivapalan, Pradeesh, additional, Priemé, Helene, additional, Wilcke, Torgny, additional, Kjeldgaard, Peter, additional, Shaker, Saher, additional, Svorre Jordan, Alexander, additional, Møller, Dina Leth, additional, Heftdal, Line Dam, additional, Madsen, Johannes Roth, additional, Bayarri-Olmos, Rafael, additional, Hansen, Cecilie Bo, additional, Pries-Heje, Mia Marie, additional, Hasselbalch, Rasmus Bo, additional, Fogh, Kamille, additional, Armenteros, Jose Juan Almagro, additional, Hilsted, Linda, additional, Sørensen, Erik, additional, Lindegaard, Birgitte, additional, Browatzki, Andrea, additional, Biering-Sørensen, Tor, additional, Frikke-Schmidt, Ruth, additional, Ostrowski, Sisse Rye, additional, Iversen, Kasper Karmark, additional, Bundgaard, Henning, additional, Nielsen, Susanne Dam, additional, Garred, Peter, additional, and Jensen, Jens-Ulrik Stæhr, additional
- Published
- 2022
- Full Text
- View/download PDF
34. Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis
- Author
-
Lerche, Christian Johann, Schwartz, Franziska, Pries-Heje, Mia Marie, Fosbøl, Emil Loldrup, Iversen, Kasper, Jensen, Peter Østrup, Høiby, Niels, Hyldegaard, Ole, Bundgaard, Henning, Moser, Claus, Lerche, Christian Johann, Schwartz, Franziska, Pries-Heje, Mia Marie, Fosbøl, Emil Loldrup, Iversen, Kasper, Jensen, Peter Østrup, Høiby, Niels, Hyldegaard, Ole, Bundgaard, Henning, and Moser, Claus
- Abstract
Patients with infective endocarditis (IE) form a heterogeneous group by age, co-morbidities and severity ranging from stable patients to patients with life-threatening complications with need for intensive care. A large proportion need surgical intervention. In-hospital mortality is 15-20%. The concept of using hyperbaric oxygen therapy (HBOT) in other severe bacterial infections has been used for many decades supported by various preclinical and clinical studies. However, the availability and capacity of HBOT may be limited for clinical practice and we still lack well-designed studies documenting clinical efficacy. In the present review we highlight the potential beneficial aspects of adjunctive HBOT in patients with IE. Based on the pathogenesis and pathophysiological conditions of IE, we here summarize some of the important mechanisms and effects by HBOT in relation to infection and inflammation in general. In details, we elaborate on the aspects and impact of HBOT in relation to the host response, tissue hypoxia, biofilm, antibiotics and pathogens. Two preclinical (animal) studies have shown beneficial effect of HBOT in IE, but so far, no clinical study has evaluated the feasibility of HBOT in IE. New therapeutic options in IE are much needed and adjunctive HBOT might be a therapeutic option in certain IE patients to decrease morbidity and mortality and improve the long-term outcome of this severe disease.
- Published
- 2022
35. Humoral response to two doses of BNT162b2 vaccination in people with HIV
- Author
-
Heftdal, Line Dam, Knudsen, Andreas Dehlbæk, Hamm, Sebastian Rask, Hansen, Cecilie Bo, Møller, Dina Leth, Pries-Heje, Mia, Fogh, Kamille, Hasselbalch, Rasmus Bo, Jarlhelt, Ida, Pérez-Alós, Laura, Hilsted, Linda Maria, Ostrowski, Sisse Rye, Gerstoft, Jan, Grønbæk, Kirsten, Bundgaard, Henning, Iversen, Kasper, Garred, Peter, Nielsen, Susanne Dam, Heftdal, Line Dam, Knudsen, Andreas Dehlbæk, Hamm, Sebastian Rask, Hansen, Cecilie Bo, Møller, Dina Leth, Pries-Heje, Mia, Fogh, Kamille, Hasselbalch, Rasmus Bo, Jarlhelt, Ida, Pérez-Alós, Laura, Hilsted, Linda Maria, Ostrowski, Sisse Rye, Gerstoft, Jan, Grønbæk, Kirsten, Bundgaard, Henning, Iversen, Kasper, Garred, Peter, and Nielsen, Susanne Dam
- Abstract
Background: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2. Methods: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2. Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%–97.0%], age- and sex-adjusted p = 0.027) of controls. Conclusions: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.
- Published
- 2022
36. Severity of anaemia and association with all-cause mortality in patients with medically managed left-sided endocarditis
- Author
-
Pries-Heje, Mia Marie, Hasselbalch, Rasmus Bo, Wiingaard, Christoffer, Fosbøl, Emil Loldrup, Glenthøj, Andreas Birkedal, Ihlemann, Nikolaj, Gill, Sabine Ute Alice, Christiansen, Ulrik, Elming, Hanne, Bruun, Niels Eske, Povlsen, Jonas Agerlund, Helweg-Larsen, Jannik, Schultz, Martin, Østergaard, Lauge, Fursted, Kurt, Christensen, Jens Jørgen, Rosenvinge, Flemming, Køber, Lars, Tønder, Niels, Moser, Claus, Iversen, Kasper, Bundgaard, Henning, Pries-Heje, Mia Marie, Hasselbalch, Rasmus Bo, Wiingaard, Christoffer, Fosbøl, Emil Loldrup, Glenthøj, Andreas Birkedal, Ihlemann, Nikolaj, Gill, Sabine Ute Alice, Christiansen, Ulrik, Elming, Hanne, Bruun, Niels Eske, Povlsen, Jonas Agerlund, Helweg-Larsen, Jannik, Schultz, Martin, Østergaard, Lauge, Fursted, Kurt, Christensen, Jens Jørgen, Rosenvinge, Flemming, Køber, Lars, Tønder, Niels, Moser, Claus, Iversen, Kasper, and Bundgaard, Henning
- Abstract
OBJECTIVE: To assess the prevalence and severity of anaemia in patients with left-sided infective endocarditis (IE) and association with mortality. METHODS: In the Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis trial, 400 patients with IE were randomised to conventional or partial oral antibiotic treatment after stabilisation of infection, showing non-inferiority. Haemoglobin (Hgb) levels were measured at randomisation. Primary outcomes were all-cause mortality after 6 months and 3 years. Patients who underwent valve surgery were excluded due to competing reasons for anaemia. RESULTS: Out of 400 patients with IE, 248 (mean age 70.6 years (SD 11.1), 62 women (25.0%)) were medically managed; 37 (14.9%) patients had no anaemia, 139 (56.1%) had mild anaemia (Hgb <8.1 mmol/L in men and Hgb <7.5 mmol/L in women and Hgb ≥6.2 mmol/L) and 72 (29.0%) had moderate to severe anaemia (Hgb <6.2 mmol/L). Mortality rates in patients with no anaemia, mild anaemia and moderate to severe anaemia were 2.7%, 3.6% and 15.3% at 6-month follow-up and 13.5%, 20.1% and 34.7% at 3-year follow-up, respectively. Moderate to severe anaemia was associated with higher mortality after 6 months (HR 4.81, 95% CI 1.78 to 13.0, p=0.002) and after 3 years (HR 2.14, 95% CI 1.27 to 3.60, p=0.004) and remained significant after multivariable adjustment. CONCLUSION: Moderate to severe anaemia was present in 29% of patients with medically treated IE after stabilisation of infection and was independently associated with higher mortality within the following 3 years. Further investigations are warranted to determine whether intensified treatment of anaemia in patients with IE might improve outcome.
- Published
- 2022
37. Effect of Influenza Vaccination on Risk of Coronavirus Disease 2019:A Prospective Cohort Study of 46 000 Healthcare Workers( )
- Author
-
Kristensen, Jonas Henrik, Hasselbalch, Rasmus Bo, Pries-Heje, Mia, Nielsen, Pernille Brok, Knudsen, Andreas Dehlbaek, Fogh, Kamille, Norsk, Jakob Boesgaard, Eiken, Aleksander, Andersen, Ove, Fischer, Thea Kølsen, Jensen, Claus Antonio Juul, Torp-Pedersen, Christian, Rungby, Jørgen, Ditlev, Sisse Bolm, Hageman, Ida, Mogelvang, Rasmus, Gybel-Brask, Mikkel, Dessau, Ram Benny, Sørensen, Erik, Harritshøj, Lene, Folke, Fredrik, Moller, Maria Elizabeth Engel, Benfield, Thomas, Ullum, Henrik, Jorgensen, Charlotte Svaerke, Ostrowski, Sisse Rye, Nielsen, Susanne Dam, Bundgaard, Henning, Iversen, Kasper, Kristensen, Jonas Henrik, Hasselbalch, Rasmus Bo, Pries-Heje, Mia, Nielsen, Pernille Brok, Knudsen, Andreas Dehlbaek, Fogh, Kamille, Norsk, Jakob Boesgaard, Eiken, Aleksander, Andersen, Ove, Fischer, Thea Kølsen, Jensen, Claus Antonio Juul, Torp-Pedersen, Christian, Rungby, Jørgen, Ditlev, Sisse Bolm, Hageman, Ida, Mogelvang, Rasmus, Gybel-Brask, Mikkel, Dessau, Ram Benny, Sørensen, Erik, Harritshøj, Lene, Folke, Fredrik, Moller, Maria Elizabeth Engel, Benfield, Thomas, Ullum, Henrik, Jorgensen, Charlotte Svaerke, Ostrowski, Sisse Rye, Nielsen, Susanne Dam, Bundgaard, Henning, and Iversen, Kasper
- Abstract
Background The purpose of this study was to assess whether influenza vaccination has an impact on the risk of coronavirus disease 2019 (COVID-19). Methods A cohort of 46 112 healthcare workers were tested for antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and filled in a survey on COVID-19 symptoms, hospitalization, and influenza vaccination. Results The risk ratio of hospitalization due to SARS-CoV-2 for influenza vaccinated compared with unvaccinated participants was 1.00 for the seasonal vaccination in 2019/2020 (confidence interval, .56-1.78, P = 1.00). Likewise, no clinical effect of influenza vaccination on development of antibodies against SARS-CoV-2 was found. Conclusions The present findings indicate that influenza vaccination does not affect the risk of SARS-CoV-2 infection or COVID-19.This cohort study of 46 112 healthcare workers examined the effect of influenza vaccination on hospitalization and symptoms due to COVID-19 and development of antibodies against SARS-CoV-2. Influenza vaccination had no effect on the specified outcomes.
- Published
- 2022
38. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
- Author
-
Harboe, Zitta Barrella, Hamm, Sebastian Rask, Pérez-Alós, Laura, Sivapalan, Pradeesh, Priemé, Helene, Wilcke, Torgny, Kjeldgaard, Peter, Shaker, Saher, Svorre Jordan, Alexander, Møller, Dina Leth, Heftdal, Line Dam, Madsen, Johannes Roth, Bayarri-Olmos, Rafael, Hansen, Cecilie Bo, Pries-Heje, Mia Marie, Hasselbalch, Rasmus Bo, Fogh, Kamille, Armenteros, Jose Juan Almagro, Hilsted, Linda, Sørensen, Erik, Lindegaard, Birgitte, Browatzki, Andrea, Biering-Sørensen, Tor, Frikke-Schmidt, Ruth, Ostrowski, Sisse Rye, Iversen, Kasper Karmark, Bundgaard, Henning, Nielsen, Susanne Dam, Garred, Peter, Jensen, Jens-Ulrik Stæhr, Harboe, Zitta Barrella, Hamm, Sebastian Rask, Pérez-Alós, Laura, Sivapalan, Pradeesh, Priemé, Helene, Wilcke, Torgny, Kjeldgaard, Peter, Shaker, Saher, Svorre Jordan, Alexander, Møller, Dina Leth, Heftdal, Line Dam, Madsen, Johannes Roth, Bayarri-Olmos, Rafael, Hansen, Cecilie Bo, Pries-Heje, Mia Marie, Hasselbalch, Rasmus Bo, Fogh, Kamille, Armenteros, Jose Juan Almagro, Hilsted, Linda, Sørensen, Erik, Lindegaard, Birgitte, Browatzki, Andrea, Biering-Sørensen, Tor, Frikke-Schmidt, Ruth, Ostrowski, Sisse Rye, Iversen, Kasper Karmark, Bundgaard, Henning, Nielsen, Susanne Dam, Garred, Peter, and Jensen, Jens-Ulrik Stæhr
- Abstract
INTRODUCTION: Responses to COVID-19 vaccination in patients with chronic pulmonary diseases are poorly characterised. We aimed to describe humoral responses following two doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired responses.METHODS: Prospective cohort study including adults with chronic pulmonary diseases and healthcare personnel as controls (1:1). Blood was sampled at inclusion, 3 weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as geometric means with 95% CI of receptor binding domain (RBD)-IgG and neutralising antibody index of inhibition of ACE-2/RBD interaction (%). A low responder was defined as neutralising index in the lowest quartile (primary outcome) or RBD-IgG <225 AU/mL plus neutralising index <25% (secondary outcome), measured at 2 months. We tested associations using Poisson regression.RESULTS: We included 593 patients and 593 controls, 75% of all had neutralising index ≥97% at 2 months. For the primary outcome, 34.7% of patients (n=157/453) and 12.9% of controls (n=46/359) were low responders (p<0.0001). For the secondary outcome, 8.6% of patients (n=39/453) and 1.4% of controls (n=5/359) were low responders (p<0.001). Risk factors associated with low responder included increasing age (per decade, adjusted risk ratio (aRR) 1.17, 95% CI 1.03 to 1.32), Charlson Comorbidity Index (per point) (aRR 1.15, 95% CI 1.05 to 1.26), use of prednisolone (aRR 2.08, 95% CI 1.55 to 2.77) and other immunosuppressives (aRR 2.21, 95% CI 1.65 to 2.97).DISCUSSION: Patients with chronic pulmonary diseases established functional humoral responses to vaccination, however lower than controls. Age, comorbidities and immunosuppression were associated with poor immunological responses.
- Published
- 2022
39. Self-assessed health status and associated mortality in endocarditis:secondary findings from the POET trial
- Author
-
Bundgaard, Johan S., Iversen, Kasper, Pries-Heje, Mia, Ihlemann, Nikolaj, Gill, Sabine U., Madsen, Trine, Elming, Hanne, Povlsen, Jonas A., Bruun, Niels E., Høfsten, Dan E., Fuursted, Kurt, Christensen, Jens J., Schultz, Martin, Rosenvinge, Flemming, Helweg‑Larsen, Jannik, Køber, Lars, Torp‑Pedersen, Christian, Fosbøl, Emil L., Tønder, Niels, Moser, Claus, Bundgaard, Henning, Mogensen, Ulrik M., Bundgaard, Johan S., Iversen, Kasper, Pries-Heje, Mia, Ihlemann, Nikolaj, Gill, Sabine U., Madsen, Trine, Elming, Hanne, Povlsen, Jonas A., Bruun, Niels E., Høfsten, Dan E., Fuursted, Kurt, Christensen, Jens J., Schultz, Martin, Rosenvinge, Flemming, Helweg‑Larsen, Jannik, Køber, Lars, Torp‑Pedersen, Christian, Fosbøl, Emil L., Tønder, Niels, Moser, Claus, Bundgaard, Henning, and Mogensen, Ulrik M.
- Abstract
Purpose: Self-assessed poor health status is associated with increased risk of mortality in several cardiovascular conditions, but has not been investigated in patients with endocarditis. We examined health status and mortality in patients with endocarditis. Methods: This is a re-specified substudy of the randomized POET endocarditis trial, which included 400 patients. Patients completed the single-question self-assessed health status from the Short-Form 36 questionnaire at time of randomization and were categorized as having poor or non-poor (excellent/very good, good, or fair) health status. Self-assessed health status and all-cause mortality were examined by a Cox regression model. Results: Self-assessed health status was completed by 266 (67%) patients with a mean age of 68.0 years (± 11.8), 54 (20%) were females, and 86 (32%) had one or more major concurrent medical conditions besides endocarditis. The self-assessed health status distribution was poor (n = 21, 8%) and non-poor (n = 245, 92%). The median follow-up was 3.3 years and death occurred in 9 (43%) and 48 (20%) patients reporting poor and non-poor health status, respectively, and mortality rates [mortality/100 person-years, 95% confidence interval (CI)] were 18.1 (95% CI 9.4–34.8) and 5.4 (95% CI 4.1–7.2), i.e., the crude hazard ratio for death was 3.4 (95% CI: 1.7–7.0, p < 0.01). Conclusion: Self-assessed poor health status compared with non-poor health status as assessed by a single question was associated with a threefold increased long-term mortality in patients with endocarditis. POET ClinicalTrials.gov number, NCT01375257. Trial registry: POET ClinicalTrials.gov number, NCT01375257.
- Published
- 2022
40. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls
- Author
-
Hamm, Sebastian Rask, Møller, Dina Leth, Pérez-Alós, Laura, Hansen, Cecilie Bo, Pries-Heje, Mia Marie, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Fogh, Kamille, Madsen, Johannes Roth, Almagro Armenteros, Jose Juan, Knudsen, Andreas Dehlbæk, Poulsen, Johan Runge, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Sørensen, Erik, Ostrowski, Sisse Rye, Harboe, Zitta Barrella, Perch, Michael, Sørensen, Søren Schwartz, Rasmussen, Allan, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, Nielsen, Susanne Dam, Hamm, Sebastian Rask, Møller, Dina Leth, Pérez-Alós, Laura, Hansen, Cecilie Bo, Pries-Heje, Mia Marie, Heftdal, Line Dam, Hasselbalch, Rasmus Bo, Fogh, Kamille, Madsen, Johannes Roth, Almagro Armenteros, Jose Juan, Knudsen, Andreas Dehlbæk, Poulsen, Johan Runge, Frikke-Schmidt, Ruth, Hilsted, Linda Maria, Sørensen, Erik, Ostrowski, Sisse Rye, Harboe, Zitta Barrella, Perch, Michael, Sørensen, Søren Schwartz, Rasmussen, Allan, Bundgaard, Henning, Garred, Peter, Iversen, Kasper, and Nielsen, Susanne Dam
- Abstract
Background: Previous studies have indicated inferior responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination in solid organ transplant (SOT) recipients. We examined the development of anti-receptor-binding domain (RBD) immunoglobulin G (IgG) after two doses of BNT162b2b in SOT recipients 6 months after vaccination and compared to that of immunocompetent controls. Methods: We measured anti-RBD IgG after two doses of BNT162b2 in 200 SOT recipients and 200 matched healthy controls up to 6 months after first vaccination. Anti-RBD IgG concentration and neutralizing capacity of antibodies were measured at first and second doses of BNT162b2 and 2 and 6 months after the first dose. T-cell responses were measured 6 months after the first dose. Results: In SOT recipients, geometric mean concentration (GMC) of anti-RBD IgG increased from first to second dose (1.14 AU/ml, 95% CI 1.08-1.24 to 11.97 AU/ml, 95% CI 7.73-18.77) and from second dose to 2 months (249.29 AU/ml, 95% CI 153.70-385.19). Six months after the first vaccine, anti-RBD IgG declined (55.85 AU/ml, 95% CI 36.95-83.33). At all time points, anti-RBD IgG was lower in SOT recipients than that in controls. Fewer SOT recipients than controls had a cellular response (13.1% vs. 59.4%, p < 0.001). Risk factors associated with humoral non-response included age [relative risk (RR) 1.23 per 10-year increase, 95% CI 1.11-1.35, p < 0.001], being within 1 year from transplantation (RR 1.55, 95% CI 1.30-1.85, p < 0.001), treatment with mycophenolate (RR 1.54, 95% CI 1.09-2.18, p = 0.015), treatment with corticosteroids (RR 1.45, 95% CI 1.10-1.90, p = 0.009), kidney transplantation (RR 1.70, 95% CI 1.25-2.30, p = 0.001), lung transplantation (RR 1.63, 95% CI 1.16-2.29, p = 0.005), and de novo non-skin cancer comorbidity (RR 1.52, 95% CI, 1.26-1.82, p < 0.001). Conclusion: Immune responses to BNT162b2 are inferior in SOT recipients compared to healthy controls, and studies aiming to det
- Published
- 2022
41. Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months:a Danish observational cohort study of 44 000 healthcare workers
- Author
-
Iversen, Kasper, Kristensen, Jonas Henrik, Hasselbalch, Rasmus Bo, Pries-Heje, Mia, Nielsen, Pernille Brok, Knudsen, Andreas Dehlbæk, Fogh, Kamille, Norsk, Jakob Boesgaard, Andersen, Ove, Fischer, Thea Køhler, Juul Jensen, Claus Antonio, Torp-Pedersen, Christian, Rungby, Jørgen, Ditlev, Sisse Bolm, Hageman, Ida, Møgelvang, Rasmus, Gybel-Brask, Mikkel, Dessau, Ram B., Sørensen, Erik, Harritshøj, Lene, Folke, Fredrik, Sten, Curt, Engel Møller, Maria Elizabeth, Benfield, Thomas, Ullum, Henrik, Jørgensen, Charlotte Sværke, Erikstrup, Christian, Ostrowski, Sisse R., Nielsen, Susanne Dam, Bundgaard, Henning, Iversen, Kasper, Kristensen, Jonas Henrik, Hasselbalch, Rasmus Bo, Pries-Heje, Mia, Nielsen, Pernille Brok, Knudsen, Andreas Dehlbæk, Fogh, Kamille, Norsk, Jakob Boesgaard, Andersen, Ove, Fischer, Thea Køhler, Juul Jensen, Claus Antonio, Torp-Pedersen, Christian, Rungby, Jørgen, Ditlev, Sisse Bolm, Hageman, Ida, Møgelvang, Rasmus, Gybel-Brask, Mikkel, Dessau, Ram B., Sørensen, Erik, Harritshøj, Lene, Folke, Fredrik, Sten, Curt, Engel Møller, Maria Elizabeth, Benfield, Thomas, Ullum, Henrik, Jørgensen, Charlotte Sværke, Erikstrup, Christian, Ostrowski, Sisse R., Nielsen, Susanne Dam, and Bundgaard, Henning
- Abstract
Objectives: Antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are a key factor in protecting against coronavirus disease 2019 (COVID-19). We examined longitudinal changes in seroprevalence in healthcare workers (HCWs) in Copenhagen and the protective effect of antibodies against SARS-CoV-2. Methods: In this prospective study, screening for antibodies against SARS-CoV-2 (ELISA) was offered to HCWs three times over 6 months. HCW characteristics were obtained by questionnaires. The study was registered at ClinicalTrials.gov, NCT04346186. Results: From April to October 2020 we screened 44 698 HCWs, of whom 2811 were seropositive at least once. The seroprevalence increased from 4.0% (1501/37 452) to 7.4% (2022/27 457) during the period (p < 0.001) and was significantly higher than in non-HCWs. Frontline HCWs had a significantly increased risk of seropositivity compared to non-frontline HCWs, with risk ratios (RRs) at the three rounds of 1.49 (95%CI 1.34–1.65, p < 0.001), 1.52 (1.39–1.68, p < 0.001) and 1.50 (1.38–1.64, p < 0.001). The seroprevalence was 1.42- to 2.25-fold higher (p < 0.001) in HCWs from dedicated COVID-19 wards than in other frontline HCWs. Seropositive HCWs had an RR of 0.35 (0.15–0.85, p 0.012) of reinfection during the following 6 months, and 2115 out of 2248 (95%) of those who were seropositive during rounds one or two remained seropositive after 4–6 months. The 133 of 2248 participants (5.0%) who seroreverted were slightly older and reported fewer symptoms than other seropositive participants. Conclusions: HCWs remained at increased risk of infection with SARS-CoV-2 during the 6-month period. Seropositivity against SARS-CoV-2 persisted for at least 6 months in the vast majority of HCWs and was associated with a significantly lower risk of reinfection.
- Published
- 2022
42. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls
- Author
-
Hamm, Sebastian Rask, primary, Møller, Dina Leth, additional, Pérez-Alós, Laura, additional, Hansen, Cecilie Bo, additional, Pries-Heje, Mia Marie, additional, Heftdal, Line Dam, additional, Hasselbalch, Rasmus Bo, additional, Fogh, Kamille, additional, Madsen, Johannes Roth, additional, Almagro Armenteros, Jose Juan, additional, Knudsen, Andreas Dehlbæk, additional, Poulsen, Johan Runge, additional, Frikke-Schmidt, Ruth, additional, Hilsted, Linda Maria, additional, Sørensen, Erik, additional, Ostrowski, Sisse Rye, additional, Harboe, Zitta Barrella, additional, Perch, Michael, additional, Sørensen, Søren Schwartz, additional, Rasmussen, Allan, additional, Bundgaard, Henning, additional, Garred, Peter, additional, Iversen, Kasper, additional, and Nielsen, Susanne Dam, additional
- Published
- 2022
- Full Text
- View/download PDF
43. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial
- Author
-
Pries-Heje, Mia M., primary, Wiingaard, Christoffer, additional, Ihlemann, Nikolaj, additional, Gill, Sabine U., additional, Bruun, Niels E., additional, Elming, Hanne, additional, Povlsen, Jonas A., additional, Madsen, Trine, additional, Jensen, Kaare T., additional, Fursted, Kurt, additional, Schultz, Martin, additional, Østergaard, Lauge, additional, Christensen, Jens J., additional, Christiansen, Ulrik, additional, Rosenvinge, Flemming, additional, Helweg-Larsen, Jannik, additional, Fosbøl, Emil L., additional, Køber, Lars, additional, Torp-Pedersen, Christian, additional, Tønder, Niels, additional, Moser, Claus, additional, Iversen, Kasper, additional, and Bundgaard, Henning, additional
- Published
- 2022
- Full Text
- View/download PDF
44. Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis
- Author
-
Lerche, Christian Johann, primary, Schwartz, Franziska, additional, Pries-Heje, Mia Marie, additional, Fosbøl, Emil Loldrup, additional, Iversen, Kasper, additional, Jensen, Peter Østrup, additional, Høiby, Niels, additional, Hyldegaard, Ole, additional, Bundgaard, Henning, additional, and Moser, Claus, additional
- Published
- 2022
- Full Text
- View/download PDF
45. Effect of Influenza Vaccination on Risk of Coronavirus Disease 2019: A Prospective Cohort Study of 46 000 Healthcare Workers
- Author
-
Kristensen, Jonas Henrik, primary, Bo Hasselbalch, Rasmus, additional, Pries-Heje, Mia, additional, Nielsen, Pernille Brok, additional, Dehlbæk Knudsen, Andreas, additional, Fogh, Kamille, additional, Boesgaard Norsk, Jakob, additional, Eiken, Aleksander, additional, Andersen, Ove, additional, Fischer, Thea Kølsen, additional, Juul Jensen, Claus Antonio, additional, Torp-Pedersen, Christian, additional, Rungby, Jørgen, additional, Ditlev, Sisse Bolm, additional, Hageman, Ida, additional, Møgelvang, Rasmus, additional, Gybel-Brask, Mikkel, additional, Dessau, Ram Benny, additional, Sørensen, Erik, additional, Harritshøj, Lene, additional, Folke, Fredrik, additional, Engel Møller, Maria Elizabeth, additional, Benfield, Thomas, additional, Ullum, Henrik, additional, Sværke Jørgensen, Charlotte, additional, Rye Ostrowski, Sisse, additional, Dam Nielsen, Susanne, additional, Bundgaard, Henning, additional, and Iversen, Kasper, additional
- Published
- 2022
- Full Text
- View/download PDF
46. Effect of influenza vaccination on risk of COVID-19 – A prospective cohort study of 46,000 health care workers
- Author
-
Kristensen, Jonas Henrik, Hasselbalch, Rasmus Bo, Pries-Heje, Mia, Nielsen, Pernille Brok, Dehlbæk Knudsen, Andreas, Fogh, Kamille, Boesgaard Norsk, Jakob, Eiken, Aleksander, Andersen, Ove, Fischer, Thea Kølsen, Juul Jensen, Claus Antonio, Torp-Pedersen, Christian, Rungby, Jørgen, Ditlev, Sisse Bolm, Hageman, Ida, Møgelvang, Rasmus, Gybel-Brask, Mikkel, Dessau, Ram Benny, Sørensen, Erik, Harritshøj, Lene, Folke, Fredrik, Engel Møller, Maria Elizabeth, Benfield, Thomas, Ullum, Henrik, Jørgensen, Charlotte Sværke, Rye Ostrowski, Sisse, Nielsen, Susanne Dam, Bundgaard, Henning, and Iversen, Kasper
- Subjects
seroprevalence ,SARS-CoV-2 ,Brief Report ,Health Personnel ,Vaccination ,virus diseases ,COVID-19 ,health care workers ,influenza vaccination ,AcademicSubjects/MED00290 ,Influenza, Human ,cohort study ,Humans ,Prospective Studies ,skin and connective tissue diseases ,hospitalization - Abstract
The purpose of this study was to assess whether influenza vaccination has an impact on the risk of coronavirus disease 2019 (COVID-19).A cohort of 46 112 healthcare workers were tested for antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and filled in a survey on COVID-19 symptoms, hospitalization, and influenza vaccination.The risk ratio of hospitalization due to SARS-CoV-2 for influenza vaccinated compared with unvaccinated participants was 1.00 for the seasonal vaccination in 2019/2020 (confidence interval, .56-1.78, P = 1.00). Likewise, no clinical effect of influenza vaccination on development of antibodies against SARS-CoV-2 was found.The present findings indicate that influenza vaccination does not affect the risk of SARS-CoV-2 infection or COVID-19.
- Published
- 2022
47. Antibody Responses and Risk Factors Associated With Impaired Immunological Outcomes Following Two Doses of BNT162b2 COVID-19 Vaccination in Patients With Chronic Pulmonary Diseases
- Author
-
Barrella Harboe, Zitta, primary, Hamm, Sebastian Rask, additional, Pérez-Alós, Laura, additional, Sivapalan, Pradeesh, additional, Priemé, Helene, additional, Wilcke, Torgny, additional, Kjeldgaard, Peter, additional, Shaker, Saher, additional, Jordan, Alexander Svorre, additional, Møller, Dina Leth, additional, Heftdal, Line Dam, additional, Madsen, Johannes Roth, additional, Olmos, Rafael Bayarri, additional, Hansen, Cecilie Bo, additional, Pries-Heje, Mia Marie, additional, Hasselbalch, Rasmus Bo, additional, Fogh, Kamille, additional, Armenteros, Jose Juan Almagro, additional, Hilsted, Linda Maria, additional, Sørensen, Erik, additional, Lindegaard Madsen, Birgitte, additional, Browatzki, Andrea, additional, Biering-Sørensen, Tor, additional, Frikke-Schmidt, Ruth, additional, Ostrowski, Sisse Rye, additional, Iversen, Kasper Karmark, additional, Bundgaard, Henning, additional, Nielsen, Susanne Dam, additional, Garred, Peter, additional, and Jensen, Jens Ulrik Stæhr, additional
- Published
- 2022
- Full Text
- View/download PDF
48. Genomic identification of streptococcal strains and relation to clinical characteristics. A substudy to The Partial Oral Treatment of Endocarditis (POET) Trial.
- Author
-
Christensen, Jens, primary, Jensen, Christian, additional, Dargis, Rimtas, additional, Nielsen, Xiaohui, additional, Pries- Heje, Mia, additional, Wiingaard, Christoffer, additional, Ihlemann, Nikolaj, additional, Gill, Sabine, additional, Bruun, Niels, additional, Elming, Hanne, additional, Povlsen, Jonas, additional, Madsen, Trine, additional, Jensen, Kaare, additional, Fuursted, Kurt, additional, Østergaard, Lauge, additional, Christiansen, Ulrik, additional, Rosenvinge, Flemming, additional, Helweg-Larsen, Jannik, additional, Fosbøl, Emil, additional, Køber, Lars, additional, Torp-Pedersen, Christian, additional, Tønder, Niels, additional, Moser, Claus, additional, Iversen, Kasper, additional, and Bundgaard, Henning, additional
- Published
- 2022
- Full Text
- View/download PDF
49. Humoral response to two doses of BNT162b2 vaccination in people with HIV
- Author
-
Heftdal, Line Dam, primary, Knudsen, Andreas Dehlbæk, additional, Hamm, Sebastian Rask, additional, Hansen, Cecilie Bo, additional, Møller, Dina Leth, additional, Pries‐Heje, Mia, additional, Fogh, Kamille, additional, Hasselbalch, Rasmus Bo, additional, Jarlhelt, Ida, additional, Pérez‐Alós, Laura, additional, Hilsted, Linda Maria, additional, Ostrowski, Sisse Rye, additional, Gerstoft, Jan, additional, Grønbæk, Kirsten, additional, Bundgaard, Henning, additional, Iversen, Kasper, additional, Garred, Peter, additional, and Nielsen, Susanne Dam, additional
- Published
- 2021
- Full Text
- View/download PDF
50. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark
- Author
-
Johannesen, Caroline Klint, primary, Rezahosseini, Omid, additional, Gybel-Brask, Mikkel, additional, Kristensen, Jonas Henrik, additional, Hasselbalch, Rasmus Bo, additional, Pries-Heje, Mia Marie, additional, Nielsen, Pernille Brok, additional, Knudsen, Andreas Dehlbæk, additional, Fogh, Kamille, additional, Norsk, Jakob Boesgaard, additional, Andersen, Ove, additional, Jensen, Claus Antonio Juul, additional, Torp-Pedersen, Christian, additional, Rungby, Jørgen, additional, Ditlev, Sisse Bolm, additional, Hageman, Ida, additional, Møgelvang, Rasmus, additional, Dessau, Ram B., additional, Sørensen, Erik, additional, Harritshøj, Lene Holm, additional, Folke, Fredrik, additional, Sten, Curt, additional, Møller, Maria Elizabeth Engel, additional, Engsig, Frederik Neess, additional, Ullum, Henrik, additional, Jørgensen, Charlotte Sværke, additional, Ostrowski, Sisse R., additional, Bundgaard, Henning, additional, Iversen, Kasper Karmark, additional, Fischer, Thea Kølsen, additional, and Nielsen, Susanne Dam, additional
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.